Serena Capici

Monza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Journal: ESMO real world data and digital oncology
Published: April 03, 2026

Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.

Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.

Journal: Current oncology (Toronto, Ont.)
Published: November 15, 2025

Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids.

Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids.

Journal: International journal of molecular sciences
Published: October 27, 2025

Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study.

Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study.

Journal: BMC cancer
Published: July 10, 2025

Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC).

Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC).

Journal: Current oncology (Toronto, Ont.)
Published: March 31, 2025

Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis.

Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis.

Journal: International journal of molecular sciences
Published: December 27, 2024

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.

Journal: Cell reports. Medicine
Published: October 21, 2022

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19.

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 21, 2022

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.

Journal: Journal of clinical medicine
Published: July 11, 2022

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything.

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything.

Journal: Cancers
Published: June 20, 2022

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.

Journal: BMC cancer
Published: April 29, 2022

Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic.

Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic.

Journal: European journal of clinical pharmacology
Published: March 07, 2022
Showing 1-12 of 21

Last Updated: 09/26/2026